AstraZeneca: Multiple Myeloma trials
The registry lists 16 Multiple Myeloma studies with AstraZeneca as lead sponsor. 8 are open to participants now and 4 have results posted.
Phase 1 13Phase 2 7Phase 3 3(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCTRecruitingNCT07764978Phase 3
- A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).RecruitingNCT07735637Phase 3
- A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple MyelomaRecruitingNCT07681596Phase 1/2
- A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)RecruitingNCT07391657Phase 3
- A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)RecruitingNCT07073547Phase 1
- A Study of GC012F in Patients With Relapsed/Refractory Multiple MyelomaRecruitingNCT06235229Phase 1/2
- AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple MyelomaRecruitingNCT06106945Phase 1/2
- AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)RecruitingNCT05850234Phase 1/2
- ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic MalignanciesCompletedNCT02362035Phase 1/2Results posted
- Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell MalignanciesCompletedNCT02328014Phase 1/2Results posted
- An Open-Label, Phase 1b Study of Acalabrutinib With and Without Dexamethasone in Subjects With Multiple MyelomaCompletedNCT02211014Phase 1Results posted
- Safety and Dose Ranging Study of Samalizumab to Treat Relapsing or Refractory CLL or MMTerminatedNCT00648739Phase 1/2Results posted
- A Study of AZD0466 in Patients With Advanced Hematologic or Solid TumorsTerminatedNCT04214093Phase 1
- MEDI2228 in Subjects With Relapsed/Refractory Multiple MyelomaCompletedNCT03489525Phase 1
- Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological MalignanciesCompletedNCT03263637Phase 1
- A Multiple Ascending Dose Study of MEDI7247 in Patients With Selected Relapsed/Refractory Hematological MalignanciesCompletedNCT03106428Phase 1